Rh Incompatibility and Hemolytic Disease of the Newborn: Risks and Prevention

Rh HDN occurs when an Rh− mother is sensitized to Rh+ fetal RBCs (from current or prior pregnancy/transfusion) and produces anti‑D IgG that crosses the placenta → fetal hemolysis.

Pathway

  1. Fetomaternal hemorrhage (delivery, trauma, procedures) exposes Rh− mother to Rh+ cells.
  2. Maternal immune response → anti‑D IgG (crosses placenta).
  3. Anti‑D binds fetal Rh+ RBCs → extravascular hemolysis (spleen/liver).
  4. Fetal anemia → high‑output heart failure → hydrops fetalis (edema, ascites, pericardial effusion).
  5. Bilirubin ↑ → kernicterus (brain damage) if severe.

Prevention

  • RhIg (RhoGAM): 300 μg IM at 28 weeks, within 72 hours post‑delivery (if baby Rh+), and after any sensitizing event (amnio, bleeding, trauma, ectopic, abortion).
  • Blocks maternal recognition of Rh+ cells.

Management if Sensitized

  • Serial maternal titers, MCA Doppler (fetal anemia surveillance).
  • Intrauterine transfusion (IUT) if anemia.
  • Early delivery if mature.
  • Phototherapy/exchange transfusion for neonatal hyperbilirubinemia.

RhIg has reduced HDN incidence >99%. Universal Rh screening in pregnancy is standard.

Pregnancy & Health - Related Articles